AstraZeneca, Bristol Myers explored $400 billion pharma tie-up
Why it matters: Any deal would face tough US antitrust scrutiny because the drugmakers compete in cancer medicines and late-stage pipelines.
Bloomberg, The Business Times (Singapore) +1
Subject